Ind-Swift Laboratories

For over 29 years, Ind-Swift Laboratories has established itself as a prominent global pharmaceutical brand, known for its dedicated and passionate efforts in the industry. With a strong legacy and financial health, the company is well-positioned to navigate future challenges and is committed to its focus on creating substantial value. A key part of its recent strategy was to completely repay its debt, freeing itself from financial constraints to focus on innovation and strategic growth. The company is now moving up the value chain by transitioning from Active Pharmaceutical Ingredients (APIs) into the high-value business of formulations, or finished medicines. To enhance its presence in this new business area, the company is amalgamating with its group company, Ind Swift Ltd, which has decades of formulation experience. This strategic pivot is backed by strong performance, with the company's revenue scaling from ₹1,185 crore in FY23 to ₹1,273 crore in FY24.;